KAP1 silencing relieves OxLDL-induced vascular endothelial dysfunction by down-regulating LOX-1

Area of Science:

• Cardiovascular Biology
• Molecular Medicine
• Cellular Biology

Background:

• KRAB domain-associated protein 1 (KAP1) is upregulated in atherosclerotic plaques.
• Endothelial dysfunction is a critical early event in atherosclerosis pathogenesis.
• Oxidative low-density lipoprotein (OxLDL) is a key inducer of endothelial dysfunction.

Purpose of the Study:

• To investigate the role of KAP1 in endothelial dysfunction induced by OxLDL.
• To determine the impact of KAP1 depletion on cellular processes relevant to atherosclerosis development.

Main Methods:

• Utilized a cell model of endothelial dysfunction using OxLDL stimulation.
• Assessed KAP1 protein levels and phosphorylation status.
• Quantified reactive oxygen species (ROS) production and adhesion molecule expression.
• Evaluated endothelial cell proliferation and migration.
• Measured expression of key markers including c-Myc, PCNA, MMP-9, LOX-1, and eNOS.

Main Results:

• KAP1 depletion significantly reduced OxLDL-induced ROS production and adhesion molecule expression in endothelial cells.
• KAP1 depletion abrogated OxLDL-mediated endothelial cell proliferation and migration.
• KAP1 depletion decreased LOX-1 levels and increased eNOS expression in OxLDL-treated endothelial cells.
• KAP1 phosphorylation and protein levels were not significantly altered by OxLDL treatment.

Conclusions:

• KAP1 is a critical mediator of OxLDL-induced endothelial dysfunction.
• KAP1 depletion ameliorates key cellular processes implicated in atherosclerosis.
• Targeting KAP1 may offer a novel therapeutic strategy for preventing or treating atherosclerosis.